Skip to main content
Premium Trial:

Request an Annual Quote

UPDATE: Incyte to Use IBM Software in New Platform

This story has been updated from an early version with comments from IBM, Incyte

NEW YORK, Sept 11 - Incyte Genomics (Nasdaq: INCY) of Palo Alto, Calif., said Monday it would incorporate IBM’s (NYSE: IBM) data management software into its new genomic research tool.

The deal represents IBM’s first partnership with the genomics industry since announcing in August that it would make an investment of $100 million in the life sciences over the next two and a half years.

“Under this agreement, DiscoveryLink is an embedded component in the new Incyte architecture,” said vice president of IBM’s life sciences division Caroline Kovac.

IBM of Somer, NY, hopes that the integration of its data management software into all of Incyte’s products will move the platform a step closer to becoming the industry standard.

“By integrating DiscoveryLink right into the Incyte product … DiscoveryLink is automatically going right into the heart of bioinformatics at the world’s major pharmaceutical companies,” said Incyte Chairman Randy Scott. “We’ve already got some software developers that are agreeing to write to the platform.”   

Kovac and Scott declined to disclose terms of the deal.

Incyte’s Genomic Knowledge Platform is designed to analyze complex biological systems, while IBM’s software is geared to help researchers integrate genomic analysis tools and diverse data sets, such as DNA sequence, gene expression, proteomics, and genetic variations.

Using Genomic Knowledge Platform with DiscoveryLink, researchers can run a single query against multiple databases and get one integrated view of information, Incyte said.

" DiscoveryLink is a key component of our genomic knowledge platform, which breaks down a major barrier to scientific discovery -- mining the increasing amounts of genomic, chemical and clinical information," Roy Whitfield, CEO of Incyte, said in a statement.

Incyte develops genomic technologies designed to enable researchers to understand the molecular basis of disease. The company also makes and markets genomic databases, data management software, microarry-based gene expression services, and related reagents.





The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.